Wang Q, Beck W T
Division of Developmental Therapeutics, Cancer Center, College of Medicine, University of Illinois at Chicago, 60607, USA.
Cancer Res. 1998 Dec 15;58(24):5762-9.
Multidrug resistance is a major obstacle to the success of cancer chemotherapy. The multidrug resistance-associated protein (MRP) has been shown to confer multidrug resistance. To study MRP gene expression at the transcriptional level, we have fused the MRP gene promoter with the luciferase reporter gene and studied its regulation. Cotransfection of MRP promoter constructs with p53 expression plasmids in p53-null human H1299 and mouse (10)1 cells demonstrated that the wild-type (wt) p53 markedly suppressed MRP promoter activity, whereas mutant p53 had little inhibitory effect. Transfections using 5' deletion mutant constructs of the MRP promoter showed that inhibition of the promoter activity by wt p53 mainly resided in the region from -91 to +103 bp, where several Sp1 transcription factor binding sites are localized. Cotransfection of the MRP promoter into Drosophila SL2 cells with an Sp1 expression vector increased the promoter activity in a dose-related manner up to approximately 200-fold. The stimulation of MRP promoter activity by Sp1 was attenuated by the cotransfection of a wt p53-expression plasmid. Furthermore, we have determined that endogenous MRP mRNA levels were down-regulated by restoration of wt p53-expression in a human lung cancer cell line. The relevance of MRP regulation in drug resistance was studied in a drug-resistant cell line, CEM/VM-1-5, that is approximately 140-fold more resistant to the epipodophyllotoxin, teniposide (VM-26), than the parental CEM cells. CEM/VM-1-5 cells express a much higher amount of MRP mRNA and protein than CEM cells, indicating that the resistant phenotype is at least partly due to increased MRP production. Transient transfection of the promoter constructs revealed that CEM/VM-1-5 cells had higher (7-fold) MRP promoter activity than CEM cells. Cotransfection of a wt p53-expression plasmid caused a reduction of MRP promoter activity in both CEM and CEM/VM-1-5 cells, but the inhibition was more than double in CEM/VM-1-5 cells compared with CEM cells. Our results demonstrated that wt p53 acts as a negative regulator of MRP gene transcription, at least in part by diminishing the effect of a powerful transcription activator Sp1. Therefore, a loss of wt p53 function and/or an increase in Sp1 activity in tumor cells could contribute to an up-regulation of the MRP gene.
多药耐药是癌症化疗成功的主要障碍。多药耐药相关蛋白(MRP)已被证明可赋予多药耐药性。为了在转录水平研究MRP基因表达,我们将MRP基因启动子与荧光素酶报告基因融合并研究其调控。在p53基因缺失的人H1299和小鼠(10)1细胞中,将MRP启动子构建体与p53表达质粒共转染表明,野生型(wt)p53显著抑制MRP启动子活性,而突变型p53几乎没有抑制作用。使用MRP启动子的5'缺失突变体构建体进行转染表明,wt p53对启动子活性的抑制主要位于-91至+103 bp区域,该区域有几个Sp1转录因子结合位点。将MRP启动子与Sp1表达载体共转染到果蝇SL2细胞中,启动子活性以剂量相关的方式增加,最高可达约200倍。Sp1对MRP启动子活性的刺激因共转染wt p53表达质粒而减弱。此外,我们已经确定,在人肺癌细胞系中恢复wt p53表达可下调内源性MRP mRNA水平。在一种耐药细胞系CEM/VM-1-5中研究了MRP调控与耐药性的相关性,该细胞系对表鬼臼毒素替尼泊苷(VM-26)的耐药性比亲代CEM细胞高约140倍。CEM/VM-1-5细胞比CEM细胞表达更高量的MRP mRNA和蛋白质,表明耐药表型至少部分归因于MRP产生增加。启动子构建体的瞬时转染显示,CEM/VM-1-5细胞的MRP启动子活性比CEM细胞高(7倍)。共转染wt p53表达质粒导致CEM和CEM/VM-1-5细胞中MRP启动子活性均降低,但与CEM细胞相比,CEM/VM-1-5细胞中的抑制作用增加了一倍多。我们的结果表明,wt p53至少部分通过减弱强大的转录激活因子Sp1的作用,作为MRP基因转录的负调节因子。因此,肿瘤细胞中wt p53功能的丧失和/或Sp1活性的增加可能导致MRP基因的上调。